Portfolia has launched Women’s Health Fund IV, described as its most focused strategy in women’s health innovation, according to the company. The new fund’s first investment is in Gameto, a clinical-stage biotech developing treatments for fertility and hormonal health.
Gameto raised $44 million in a Series C round, bringing its total funding to $127 million. Its lead program, Fertilo, uses engineered ovarian support cells to mature eggs outside the body. The company claims this approach could cut the typical two-week IVF hormone protocol to just 2–3 days. Gameto has begun enrolling U.S. patients in a pivotal Phase 3 trial, following earlier use in Australia and Latin America, where five babies have been born and more than 20 pregnancies reported.
Portfolia said that Women’s Health Fund IV builds on its role as the first U.S. venture capital fund dedicated exclusively to women’s health. The firm has already made 46 investments across fertility, childbirth, menopause, autoimmune disease, oncology, cardiovascular health, and other areas.
The company noted that women’s health represents a global market exceeding $600 billion, yet currently attracts only 2 percent of venture capital funding. Women’s Health Fund IV will target women-specific conditions, diseases that affect women differently, and conditions that disproportionately impact women.
The fund is open to accredited investors, qualified purchasers, and family offices, Portfolia said.
